- $1.79bn
- $1.74bn
- $1.80m
Brief: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Brief: Inhibrx to host webcast presentation to provide clinical update on INBRX-106 HexAgon study in first line HNSCC
Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say
U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway
U.S. STOCKS ON THE MOVE-Certara, Otis, Twilio
U.S. STOCKS ON THE MOVE-Best Buy, Teleflex, Philip Morris
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Inhibrx rises as experimental drug tied to Merck’s Keytruda catches drugmakers' eye
Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Brief: Inhibrx To Host Webcast Presentation To Provide Clinical Update On Ozekibart In Late Line Colorectal Cancer